NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
523
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
stocks
New production imminent for undervalued ASX gas play
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,324.60 | 40.80 | 0.44% |
CAC 40 | 8,201.98 | 27.78 | 0.34% |
DAX 40 | 24,226.46 | 395.47 | 1.66% |
Dow JONES (US) | 46,469.36 | 278.75 | 0.60% |
FTSE 100 | 9,405.20 | 50.63 | 0.54% |
HKSE | 25,858.83 | 611.73 | 2.42% |
NASDAQ | 22,915.18 | 235.21 | 1.04% |
Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
S&P 500 | 6,715.45 | 51.44 | 0.77% |
S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
SSE Composite Index | 3,863.89 | 24.14 | 0.63% |